Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market, By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements), Application (Congenital Bilateral Absence of the Vas Deferens, Cystic Fibrosis, Hereditary Pancreatitis, Others), Dosage (Liquids, Sprays, Injectables, Others), Route of Administration (Oral, Inhaled), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Analysis and Size
Growing awareness regarding this progressive genetic disease and the rising adoption of drug therapies are some of the major factors pushing the cystic fibrosis market growth. It has been witnessed that based on the route of administration, the oral segment is boosting the market for cystic fibrosis. Additionally, the approval of the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator has changed the landscape of cystic fibrosis in the era of precision medicine.
Data Bridge Market Research analyses a growth rate in cystic fibrosis transmembrane conductance regulator (CFTR) market in the forecast period 2023-2030. The expected CAGR of cystic fibrosis transmembrane conductance regulator (CFTR) market is tend to be around 24.8% in the mentioned forecast period. The market value is USD 7.18 billion in 2022, and it would grow upto USD 42.23 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023-2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements), Application (Congenital Bilateral Absence of the Vas Deferens, Cystic Fibrosis, Hereditary Pancreatitis, Others), Dosage (Liquids, Sprays, Injectables, Others), Route of Administration (Oral, Inhaled), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Genentech Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Johnson & Johnson Private Limited (U.S.), Abbvie, Inc (U.S.), Mylan N.V. (U.S.), Pharmaxis Ltd (Australia), Vertex Pharmaceuticals Incorporated (U.S.)
|
|
Market Opportunities
|
|
Market Definition
The cystic fibrosis transmembrane conductance regulator (CFTR) gene codes for an ABC transporter-class ion channel protein which conducts chloride and bicarbonate ions across epithelial cell membranes. The CFTR protein is made as per the instructions from the CFTR gene. This protein acts as a channel between cells, generating sweat, saliva, mucus, tears, and digestive enzymes. Chloride ions are negatively charged and are transported into and out of cells through this channel.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Dynamics
Drivers
- Increased Cases of Cystic Fibrosis
As per the records of Cystic Fibrosis Patient Registry, more than 30,000 people are at present suffering from this condition in the U.S., while more than 70,000 people are claimed to be suffering from it globally. Additionally, around 1000 new cases of the disease are diagnosed each year. The rising occurrence of this disease is likely to increase the demand for combination treatments that will boost the industry progression in the coming years.
- Increasing Demand of Oral Segment
The oral segment is dominating the market for cystic fibrosis. The increased efficiency of orally administered medication in improving the quality of life and decreasing the intensity of symptoms is providing boost to the market growth of cystic fibrosis. In addition to this, the wide accessibility of oral medications such as Kalydeco, Ataluren, and N-acetylcysteine is also extending the development of the market. Furthermore, the increasing drift of patients towards oral treatments over intravenous therapy is resulting in the huge market growth. This boost the market growth.
Opportunities
- Growing R&D Activities on Cystic Fibrosis
Growing spending on R&D research in the industry and other technological advancements in this diseased condition will open new scopes of growth for industry participants. Growing funding for R&D projects on cystic fibrosis drugs and other government initiatives will boost the market growth. For instance, North American Cystic Fibrosis Conference (NACFC) has started providing educational forums to the cystic fibrosis community, allowing them to share the latest developments in the R&D space. Furthermore, the U.S. FDA approved a new triple combination therapy, i.e., Trikafta, in October 2019 for treating cystic fibrosis patients. This novel therapy will increase the survival possibilities of these patients. In August 2021, Cystic Fibrosis Canada insisted on standardized adoption recommendations for patient access to Trikafta to improve patients' quality of life and increase the adoption rate of several treatment procedures.
Restraints/Challenges
- Discontinuation of Drug Trials
The drug development associated with the disease has faced many obstacles such as many therapies that have failed to reveal efficacy or were related with major toxicity. Thus, this hampers the growth of the market.
This cystic fibrosis transmembrane conductance regulator (CFTR) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cystic fibrosis transmembrane conductance regulator (CFTR) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2020, Roche and Abbvie announced the partnership and also acquired the TMEM 16A product portfolio. It is used in cystic fibrosis with a rare CFTR genotype and associated respiratory illnesses. This acquisition helped to boost the prospects.
- In 2019, AbbVie and Cystic Fibrosis Foundation (CFF) formed a huge strategic alliance to develop CFTR molecule. This partnership is bound to surge the product developments in the market
Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Scope
The cystic fibrosis transmembrane conductance regulator (CFTR) market is segmented on the basis of drug class, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- CFTR Modulators
- Kalydeco
- Orkambi
- Mucolytics
- Acetylcysteine
- Bromhexine
- Ambroxol
- Bronchodilators
- Beta-2 agonists
- Anticholinergics
- Pancreatic Enzyme Supplements
- Creon
- Zenpep
Application
- Congenital Bilateral Absence of the Vas Deferens
- Cystic Fibrosis
- Hereditary Pancreatitis
- Others
Dosage
- Liquids
- Sprays
- Injectables
- Others
Route of Administration
- Oral
- Inhaled
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Regional Analysis/Insights
The cystic fibrosis transmembrane conductance regulator (CFTR) market is analyzed and market size insights and trends are provided by drug class, application, dosage, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the cystic fibrosis transmembrane conductance regulator (CFTR) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific will be expecting positive growth for cystic fibrosis transmembrane conductance regulator (CFTR) market throughout the forecasted period due to the several government initiatives in countries to expand lifestyle of people surviving with rare diseases. The wide adoption of advanced technologies, digital tools for quick diagnosis, and major improvements in virtual consultations result in market growth.
North America dominates the market due to the growing research and development activities. Furthermore, the increasing presence of major market players will further enhance this region's growth rate.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Share Analysis
The cystic fibrosis transmembrane conductance regulator (CFTR) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cystic fibrosis transmembrane conductance regulator (CFTR) market.
Key players operating in the cystic fibrosis transmembrane conductance regulator (CFTR) market include:
- Kirin Holdings Company, Limited (Japan)
- Vericel Corporation (U.S.)
- Mereo Biopharma Group PLC (U.K.)
- Novartis AG (Switzerland)
- AM-Pharma B.V (Netherlands)
- Alexion Pharmaceuticals, Inc. (U.S.)
- Bayer AG (Germany)
- Pfizer, Inc (U.S.)
SKU-